Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Cancer heterogeneity: converting a limitation into a source of biologic information

Fig. 3

Temporal course of serum tumor marker levels and radiologic tumor mass measuring in a BRAF V600E-mutated malignant melanoma during targeted therapy with a BRAF-inhibitor and a PD1-checkpoint-inhibitor (90% PDL1-positivity of tumor cells). A rise in serum marker levels indicates emerging resistance to therapy and is confirmed by CT-scan measurement of metastasis volume. S actual surgery of recurrent tumor, LB potential time points for early liquid biopsy analysis of temporal genetic heterogeneity

Back to article page